Category | Variable | Sub variable | Value |
---|---|---|---|
Demographics | Body Mass Index | 25[22–27] | |
Sex | Male (n, %) | 259(54.9) | |
Female (n,%) | 213(45.1) | ||
Age (years) | 71[64–76] | ||
Smoking | Non-smoker (n, %) | 317(67.2) | |
Active smoker* (n, %) | 116(24.6) | ||
Unknown (n, %) | 39(8.3) | ||
Alcohol use | Non (n, %) | 106(22.5) | |
1–21 drinks/week n, (n,%) | 193(40.9) | ||
> 21 drink/week (n, %) | 16(3.4) | ||
Unknown (n,%) | 158(33.3) | ||
Charlson comorbidity index | 1[0–2] | ||
ASA-score | 2[2–3] | ||
Treatment related | Hospital length of stay (days) | 10[7–18] | |
Duration of surgery (minutes) | 278[236–323] | ||
Portal vein resection performed | Yes (n,%) | 122(26.0) | |
No (n,%) | 351(74.0) | ||
Epidural analgesia | Yes (n,%) | 373(79.0) | |
No (n,%) | 99(21.0) | ||
Type of anesthesia | Intravenous and inhalation (n,%) | 170(36.0) | |
Total Intravenous (n,%) | 273(57.8) | ||
Unknown (n,%) | 29(6.1) | ||
Perioperative transfusions | Yes (n, %) | 84(17.8) | |
No (n, %) | 388(82.2) | ||
Pre-transfusion hemoglobin levels | >= 5.6 mmol/l (n,%) | 16(19.0) | |
>= 4.3 and < 5.6 mmol/l (n,%) | 59(70.2) | ||
< 4.3 mmol/l (n,%) | 9(10.7) | ||
Critical bleeding | Yes (n,%) | 33(8.0) | |
No (n,%) | 440(93.0) | ||
Tumor related | Preoperative chemotherapy | Yes (n,%) | 43(9.1) |
No (n,%) | 429(90.9) | ||
Postoperative chemotherapy | Yes (n,%) | 370(78.4) | |
No (n,%) | 102(21.6) | ||
Type of resection | Pancreaticoduodenectomy (n,%) | 263(55.7) | |
Total pancreatectomy (n,%) | 62(13.1) | ||
Distal pancreatectomy (n,%) | 77(16.3) | ||
Unknown (n,%) | 71(14.9) | ||
Tumor T-stage | T1(n,%) | 30(6.4) | |
T2(n,%) | 86(18.2) | ||
T3(n,%) | 243(51.5) | ||
T4(n,%) | 9(1.9) | ||
Unknown (n,%) | 104(22.0) | ||
Tumor N-stage | N0 (n,%) | 104(22.0) | |
N1 (n,%) | 199(42.2) | ||
N2 (n,%) | 59(12.5) | ||
Unknown (n,%) | 110(23.3) | ||
Resection outcome | R0 (n,%) | 211(44.7) | |
R1 (n,%) | 135(28.6) | ||
Unknown | 126(26.7) | ||
Follow-up | Status at end of follow-up | Alive (n,%) | 196(41.5) |
Dead (n,%) | 276(58.5) | ||
Follow-up time (months) | 21[13–35] |